Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ME2 | P23368 | 1/20 | 0.56 |
| ▸ | ME1 | P48163 | 1/20 | 0.56 |
| ▸ | ME3 | Q16798 | 1/20 | 0.56 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613561 | 0.87 | GAA (0.55) | MEN1KMT2AUSP2GAAPOLB | |
| SCHEMBL29129166 | 0.87 | GAA (0.55) | MEN1KMT2AUSP2GAAPOLB | |
| SCHEMBL19143918 | 0.86 | KMT2A (0.52) | MEN1KMT2APOLBL3MBTL1ALDH1A1 | |
| SCHEMBL172099 | 0.86 | POLB (0.64) | MEN1KMT2AGAAPOLBL3MBTL1 | |
| SCHEMBL10721826 | 0.85 | MEN1 (1.00) | MEN1KMT2AUSP2GAAPOLB | |
| SCHEMBL3216431 | 0.85 | GAA (0.53) | MEN1KMT2AUSP2GAAPOLB | |
| SCHEMBL30257328 | 0.85 | GAA (0.53) | MEN1KMT2AUSP2GAAPOLB | |
| SCHEMBL2616222 | 0.85 | FKBP1A (0.65) | MEN1KMT2AGAAALDH1A1LMNA | |
| SCHEMBL15172585 | 0.84 | ALDH1A1 (0.63) | MEN1KMT2APOLBL3MBTL1KDM4E | |
| SCHEMBL29129121 | 0.83 | GAA (0.54) | MEN1KMT2AGAAPOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3082805-B1 | SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME | INST FOR DRUG DISCOVERY LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-2448581-B1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2448581-B1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-9115086-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115086-B2 | Therapeutic compositions and related methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. | 2012-06-28 | — | — | US | disclosed |
| EP-2448581-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011002816-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2011002816-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165324-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS OF USE | PDK2, PDK1, PDK3 | MEN1 3936/4885KMT2A 880/4885USP2 3122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.